Published in Cancer Weekly, June 1st, 2010
"This second amendment to our current patent licensing agreement is quite important for the development of Advaxis' platform technology," commented Advaxis Chairman/CEO Thomas A. Moore. "Although we are currently in a solid position regarding our technology, IP position and exclusive licensee status...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.